Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

Abstract

IntroductionThe phase II JO25567 study compared the efficacy and safety of erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).ObjectiveOur objective is to provide updated analyses of safety and the assessment of manageability of specific adverse events.MethodsPatients with stage IIIB/IV or recurrent, non-squamous, EGFR mutation-positive NSCLC were randomized to receive erlotinib plus bevacizumab or erlotinib. The primary endpoint was progression-free survival. Adverse event frequency rates, predictability and manageability, reasons for discontinuation, time to onset, and outcomes of specific adverse events were analyzed.ResultsThe safety analysis population comprised 152 randomized patients (75 erlotinib plus bevacizumab; 77 erlotinib) who received at least one dose of study drug between February 2011 and March 2012. There was no difference in overall incidence of serious adverse events between arms, but more grade 3 or higher adverse events were reported with erlotinib plus bevacizumab (90.7%) than with erlotinib (53.2%), primarily due to grade 3 hypertension. Hypertension was controllable with antihypertensive medications in most cases. Proteinuria and bleeding were also more frequently reported with erlotinib plus bevacizumab than with erlotinib but were manageable and did not lead to early discontinuations.ConclusionsThe addition of bevacizumab to erlotinib prolonged progression-free survival in EGFR mutation-positive NSCLC. Follow-up safety data were consistent with the known safety profiles of both erlotinib and bevacizumab in NSCLC; this combination appeared to be manageable, and treatment was well tolerated.JapicCTI-111390.Electronic supplementary materialThe online version of this article (doi:10.1007/s40264-017-0596-0) contains supplementary material, which is available to authorized users.

Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase‐positive lung cancer

“…However, following a single dose of bevacizumab, the patient's brain radiation necrosis showed improvement, suggesting that a single bevacizumab dose can also be effective. In a phase 2 study, a combination of erlotinib plus bevacizumab resulted in grade 3 or higher adverse events, the most frequent ones being hypertension and proteinuria . Consistent with this previous report, hypertension and proteinuria were the most frequently reported adverse events among our four patients as well.…”

Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report

“…The updated safety results of JO25567 showed high frequency of hypertension and bleeding occurred in patients treated with bevacizumab plus erlotinib but were manageable. 24 Consistent with JO25567, the hypertension was in control in present case, and there were no other serious adverse events.…”

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

“…Five journal articles (27)(28)(29)(30)(31), one conference abstract (32), and an oral presentation at the 2019 ESMO congress (33) met the inclusion criteria, including two Japanese studies, one Chinese study, one American study, and one international multicenter study. Three trials included brain metastatic patients.…”